BioSight
Companies
RELMADA THERAPEUTICS, INC. logo

RLMD

NASDAQCORAL GABLES, FL
RELMADA THERAPEUTICS, INC.

Relmada is a clinical-stage biotech company developing two drug candidates: NDV-01, a novel intravesical chemotherapy formulation for non-muscle-invasive bladder cancer currently in Phase 2, and sepranolone, a neurosteroid in Phase 2b-ready status for neurological disorders including Prader-Willi syndrome and Tourette syndrome. The company recently pivoted its strategy in early 2025, terminating its previous lead program and acquiring these new candidates to diversify its pipeline and leverage its drug development expertise.

Price history not yet available for RLMD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar